OncoSec Reports Result of Keytruda + TAVO in P-II KEYNOTE-890 Study for Refractory Metastatic Triple Negative Breast Cancer

 OncoSec Reports Result of Keytruda + TAVO in P-II KEYNOTE-890 Study for Refractory Metastatic Triple Negative Breast Cancer

OncoSec Reports Result of Keytruda + TAVO in P-II KEYNOTE-890 Study for Refractory Metastatic Triple Negative Breast Cancer

Shots:

  • The P-II KEYNOTE-890 study results involve assessing of Keytruda (200mg, IV) + TAVO (tavokinogene telseplasmid) in 25 patients with heavily pretreated, CT/radiotherapy refractory mTNBC who failed an average of 3.5 prior lines of CT
  • The P-II KEYNOTE-890 study result:  @3mos. 20% + tumor reduction; two patients showed 66% tumor reduction including reduction of liver lesions; well tolerated
  • OncoSec’s TAVO (tavokinogene telseplasmid) is an immunotherapy platform, allowing the intratumoral delivery of IL-12 and Keytruda (pembrolizumab) is mAb targeting PD-1, blocking the interaction b/w PD-1 and its ligands, PD-L1 and PD-L2 thus activating T-lymphocytes affecting both tumor & healthy cells

Click here to read full press release/ article | Ref: OncoSec | Image: OncoSec Medical Incorporated (ONCS)

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post